Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eutectic of diflunisal and pyridine formamide compounds and preparation method thereof

A technology of pyridinecarboxamide and diflunisal, which is applied in the field of chemical pharmaceuticals, can solve problems in the initial stage and achieve good solubility effects

Inactive Publication Date: 2014-06-18
SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
View PDF8 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, drug crystal form research is relatively mature and valued in the European and American pharmaceutical circles, but it is still in its infancy in the domestic pharmaceutical circles

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eutectic of diflunisal and pyridine formamide compounds and preparation method thereof
  • Eutectic of diflunisal and pyridine formamide compounds and preparation method thereof
  • Eutectic of diflunisal and pyridine formamide compounds and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0052] Preparation of co-crystals with diflunisal and nicotinamide: the reactant diflunisal and nicotinamide are fed according to the material ratio of 1:1. Accurately weigh 131.0 mg of diflunisal and 63.9 mg of nicotinamide and dissolve them in 2.6 ml and 1.1 ml of ethanol, respectively, and ultrasonicate for 10 min to fully dissolve the two, and then slowly add the ethanol solution of nicotinamide to the two In the ethanol solution of flunisal, mix thoroughly, let it stand for one day, filter, rinse with a small amount of ethanol, and then place the filtered product in a vacuum drying oven at 40°C for one day to dry.

[0053] Figures 1 to 5 They are respectively the X-ray diffraction spectrum and solid-state nuclear magnetic resonance CP-MAS of diflunisal / nicotinamide co-crystal and its bulk drug in Example 1. 13 C spectrum, infrared spectrum and thermogram.

[0054] Depend on Figure 1 to Figure 5 It can be seen that the melting point of diflunisal and nicotinamide co-c...

example 2

[0056] Preparation of co-crystal with diflunisal and nicotinamide: the reactant diflunisal and nicotinamide are fed according to the material ratio of 2:1. Accurately weigh 131.0 mg of diflunisal and 32 mg of nicotinamide and dissolve them in 2.6 ml and 1.1 ml of ethanol, respectively, and ultrasonicate for 10 min. In the ethanol solution of flunisal, mix thoroughly, let it stand for one day, filter, rinse with a small amount of ethanol, and then place the filtered product in a vacuum drying oven at 40°C for one day to dry.

example 3

[0058] Preparation of co-crystal with diflunisal and isonicotine: the reactant diflunisal and isonicotine are fed according to the material ratio of 1:1. Accurately weigh 196.5 mg of diflunisal and 95.8 mg of isonicotine and dissolve them in 2.6 ml and 1.1 ml of ethanol respectively, and ultrasonicate for 10 min to fully dissolve the two, then slowly add the ethanol solution of isonicotine dropwise Put it into the ethanol solution of diflunisal, mix well, let stand for one day, filter, wash with a small amount of ethanol, then place the filtered product in a vacuum drying oven at 40°C, and dry for one day.

[0059] Figures 6 to 10 They are the X-ray diffraction spectrum and the solid-state nuclear magnetic resonance CP-MAS of diflunisal / isonicotine co-crystal and its bulk drug in Example 3 respectively. 13 C spectrum, infrared spectrum, thermogram and dissolution curve in water.

[0060] Depend on Figure 6 to Figure 10 It can be seen that the melting point of diflunisal / i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the chemical pharmaceutical technical field and in particular relates to an eutectic medicine of 2 ',4 '- difluoro-4-hydroxyl-3-biphenyl carboxylic acid and pyridine carboxamide compounds and a preparation method thereof. The eutectic medicine prepared in the invention is obviously improved in solubility.

Description

technical field [0001] The application belongs to the technical field of chemical pharmacy, and in particular relates to a co-crystal of diflunisal (2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid) and pyridinecarboxamide compounds and a preparation method thereof. Background technique [0002] Drug solubility is one of the important factors affecting drug absorption and bioavailability. Statistics show that in current drug development, 35% - 40% of new drugs have low solubility or poor permeability, which significantly reduces the bioavailability of drugs and seriously affects the effective absorption of active drugs in the human body. Therefore, improving the solubility and bioavailability of poorly soluble drugs is one of the important directions of pharmaceutical research. [0003] At present, there are many methods for solubilizing insoluble drugs. Solid-state dispersion technology, cyclodextrin inclusion technology, liposome technology, micronization technology, et...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C65/105C07C51/43C07D213/82C07D213/81
CPCC07D213/82C07D213/81
Inventor 张海禄汪莲艳邓宗武
Owner SUZHOU INST OF NANO TECH & NANO BIONICS CHINESE ACEDEMY OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com